Literature DB >> 2419898

Monoclonal antibody MB19 detects genetic polymorphism in human apolipoprotein B.

S G Young, S J Bertics, L K Curtiss, D C Casal, J L Witztum.   

Abstract

Using a specific monoclonal antibody (MB19) against human apolipoprotein B (apo B), we have detected a genetic polymorphism in human low density lipoprotein (LDL). MB19 bound to LDL from different individuals in one of three distinct patterns of immunoreactivity: strong, weak, and intermediate. Scatchard analysis revealed that LDLs with strong and with weak binding patterns differed 10-fold in their affinity for MB19, but both bound the same total amount of antibody (about one mole of MB19 per mole of apo B). LDL showing the intermediate binding pattern yielded a curvilinear Scatchard plot that could be resolved into two distinct components with affinities similar to those of LDLs exhibiting only the high- or only the low-affinity binding of MB19. LDL chemical composition was similar for all three MB19 binding patterns, and the polymorphism remained after removal of LDL lipid or carbohydrate. Analysis of plasmas from 77 unrelated individuals indicated that 40% of them bound MB19 with low affinity, 23% with high affinity, and 36% with intermediate or "hybrid" affinity. Family studies showed that the three MB19 binding patterns result from codominant transmission of two common apo B alleles, each coding for an allotype with different affinity for MB19, conditionally designated here MB19(1) (high affinity) and MB19(2) (low affinity).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2419898      PMCID: PMC323019          DOI: 10.1073/pnas.83.4.1101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.

Authors:  R J HAVEL; H A EDER; J H BRAGDON
Journal:  J Clin Invest       Date:  1955-09       Impact factor: 14.808

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Monoclonal antibodies to human plasma low-density lipoproteins. I. Enhanced binding of 125I-labeled low-density lipoproteins by combined use of two monoclonal antibodies.

Authors:  S J Mao; J G Patton; J J Badimon; B A Kottke; M C Alley; A D Cardin
Journal:  Clin Chem       Date:  1983-11       Impact factor: 8.327

4.  Characterization of antigenic determinants of human apolipoprotein B. Distribution on tryptic fragments of low density lipoprotein.

Authors:  R Theolis; P K Weech; Y L Marcel; R W Milne
Journal:  Arteriosclerosis       Date:  1984 Sep-Oct

5.  Anti-apoprotein B monoclonal antibodies detect human low density lipoprotein polymorphism.

Authors:  V N Schumaker; M T Robinson; L K Curtiss; R Butler; R S Sparkes
Journal:  J Biol Chem       Date:  1984-05-25       Impact factor: 5.157

Review 6.  Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol.

Authors:  J L Goldstein; M S Brown
Journal:  J Lipid Res       Date:  1984-12-15       Impact factor: 5.922

7.  Immunochemical heterogeneity of human plasma apolipoprotein B. II. Expression of apolipoprotein B epitopes on native lipoproteins.

Authors:  B P Tsao; L K Curtiss; T S Edgington
Journal:  J Biol Chem       Date:  1982-12-25       Impact factor: 5.157

8.  Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia.

Authors:  B Teng; G R Thompson; A D Sniderman; T M Forte; R M Krauss; P O Kwiterovich
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

9.  Cholestyramine-induced changes in low density lipoprotein composition and metabolism. I. Studies in the guinea pig.

Authors:  J L Witztum; S G Young; R L Elam; T E Carew; M Fisher
Journal:  J Lipid Res       Date:  1985-01       Impact factor: 5.922

10.  Immunochemical heterogeneity of human plasma apolipoprotein B. I. Apolipoprotein B binding of mouse hybridoma antibodies.

Authors:  L K Curtiss; T S Edgington
Journal:  J Biol Chem       Date:  1982-12-25       Impact factor: 5.157

View more
  15 in total

1.  Familial hypobetalipoproteinemia caused by a mutation in the apolipoprotein B gene that results in a truncated species of apolipoprotein B (B-31). A unique mutation that helps to define the portion of the apolipoprotein B molecule required for the formation of buoyant, triglyceride-rich lipoproteins.

Authors:  S G Young; S T Hubl; R S Smith; S M Snyder; J F Terdiman
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

Review 2.  Use of monoclonal antibodies in genetic research with nonhuman primates.

Authors:  R M Sharp
Journal:  Genetica       Date:  1987-08-31       Impact factor: 1.082

3.  Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation.

Authors:  M F Linton; R Gish; S T Hubl; E Bütler; C Esquivel; W I Bry; J K Boyles; M R Wardell; S G Young
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

4.  Familial defective apolipoprotein B-100: enhanced binding of monoclonal antibody MB47 to abnormal low density lipoproteins.

Authors:  K H Weisgraber; T L Innerarity; Y M Newhouse; S G Young; K S Arnold; R M Krauss; G L Vega; S M Grundy; R W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

5.  Apolipoprotein B amino acid 3611 substitution from arginine to glutamine creates the Ag (h/i) epitope: the polymorphism is not associated with differences in serum cholesterol and apolipoprotein B levels.

Authors:  C F Xu; N Nanjee; M J Tikkanen; J K Huttunen; P Pietinen; R Bütler; F Angelico; M Del Ben; B Mazzarella; R Antonio
Journal:  Hum Genet       Date:  1989-07       Impact factor: 4.132

6.  Prevention of experimental cerebral malaria by anticytokine antibodies. Interleukin 3 and granulocyte macrophage colony-stimulating factor are intermediates in increased tumor necrosis factor production and macrophage accumulation.

Authors:  G E Grau; V Kindler; P F Piguet; P H Lambert; P Vassalli
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

7.  Genetic analysis of a kindred with familial hypobetalipoproteinemia. Evidence for two separate gene defects: one associated with an abnormal apolipoprotein B species, apolipoprotein B-37; and a second associated with low plasma concentrations of apolipoprotein B-100.

Authors:  S G Young; S J Bertics; L K Curtiss; B W Dubois; J L Witztum
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

8.  Exclusion of linkage between the human apolipoprotein B gene and abetalipoproteinemia.

Authors:  L S Huang; P A Jänne; J de Graaf; M Cooper; R J Deckelbaum; H Kayden; J L Breslow; R J Decklebaum
Journal:  Am J Hum Genet       Date:  1990-06       Impact factor: 11.025

9.  Modification of the apolipoprotein B gene in HepG2 cells by gene targeting.

Authors:  R V Farese; L M Flynn; S G Young
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

10.  Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a).

Authors:  M F Linton; R V Farese; G Chiesa; D S Grass; P Chin; R E Hammer; H H Hobbs; S G Young
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.